IMMULITE 2000 3gAllergy Specific IgE Vantage; IMMULITE 2000 Systems Peanut Allergen (F13)
Siemens Healthcare Diagnostics Products, Ltd. · Decision date Sep 4, 2026
What did the FDA decide?
FDA recorded a substantially equivalent (SESE) decision on September 4, 2026 for K260331, a traditional 510(k) submitted February 2, 2026 by Siemens Healthcare Diagnostics Products, Ltd. The device is the IMMULITE 2000 3gAllergy Specific IgE Vantage with IMMULITE 2000 Systems Peanut Allergen (F13), a quantitative chemiluminescent immunoassay for allergen-specific IgE to whole peanut extract in human serum, run on the IMMULITE 2000 XPi System under product code DHB, Class II, 21 CFR 866.5750. Clearance is not a PMA approval.
The comparison document names K013134, the IMMULITE 2000 Allergen Specific IgE Kit, as predicate, with chemiluminescence, serum sample type, 65-minute process time, detection antibody and bead chemistry listed as the same. Recorded differences are the F13 whole peanut extract allergen, an added recombinant sheep monoclonal high-biotin-affinity accessory reagent, and a 30 µL versus 50 µL sample volume. A separate CLIA listing shows the assay as moderate complexity effective September 11, 2026. The provided materials give no analytical performance results, so accuracy and clinical performance remain unknown here.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- Immunology
- Decision date
- Sep 4, 2026
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- K260331
- Regulatory pathway
- 510(k) premarket notification
- Product code
- DHB
- Decision code
- SESE
- Decision date
- Sep 4, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Test, Radioallergosorbent (Rast) Immunological.
- Product code
- DHB
- FDA device class
- 2
FDA decision timeline
K260331 received
Application receipt date recorded by FDA.
K260331 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code DHB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Siemens Healthcare Diagnostics Products, Ltd. | 510(k) clearance | Nov 2, 2026 | FDA | |
| Hycor Biomedical | 510(k) clearance | Jul 24, 2026 | FDA | |
| Hycor Biomedical | 510(k) clearance | Jul 21, 2026 | FDA | |
| Hycor Biomedical | 510(k) clearance | Jun 18, 2026 | FDA | |
| Hycor Biomedical | 510(k) clearance | May 15, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Siemens Healthcare Diagnostics Products, Ltd.
- Headquarters
- Not reported
- Brand website
- siemens-healthineers.com
- FDA applicant address
- Llanberis
Sources and methodology
- Original FDA record: K260331
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records

